2024 年呋喹替尼海外销售额达2.82 亿美元武田制药FY2024 Q3 财报(武田制药FY2024 为自然年2024Q2-2025Q1)显示,2024Q2-Q4 呋喹替尼海外收入361 亿日元,即2.34 亿美元(以2 月4 日美元兑日元汇率计算),其中美国收入325 亿日元(占比90%);单Q4 收入130 亿日元(约0.84 亿美元),环比+17.1%。基于公司核心产品呋喹替尼于海外市场...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.